These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation. Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374 [TBL] [Abstract][Full Text] [Related]
18. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603 [TBL] [Abstract][Full Text] [Related]
19. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?]. Thomas X Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550 [TBL] [Abstract][Full Text] [Related]
20. Ponatinib in the therapy of chronic myeloid leukemia. Poch Martell M; Sibai H; Deotare U; Lipton JH Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]